Photo Release -- Merrion Announces License Agreement With Novo Nordisk to Develop Oral Formulation of GLP-1 Receptor Agonist(s) -- Novo Nordisk Makes Equity Investment in Merrion
January 16, 2009 02:00 ET
|
Merrion Pharmaceuticals plc
DUBLIN, Ireland, Jan. 16, 2009 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals (IEX:MERR) and Novo Nordisk A/S (NYSE:NVO), a world leader in diabetes, have entered into a Development and License Agreement...
Merrion Announces License Agreement With Novo Nordisk to Develop Oral Formulation of GLP-1 Receptor Agonist(s) -- Novo Nordisk Makes Equity Investment in Merrion
January 16, 2009 02:00 ET
|
Merrion Pharmaceuticals plc
DUBLIN, Ireland, Jan. 16, 2009 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals
(IEX:MERR) and Novo Nordisk A/S (NYSE:NVO), a world leader in diabetes, have
entered into a Development and License...
Photo Release -- Merrion Announces License Agreement With Novo Nordisk to Develop Oral Formulation of Insulin Analogues
November 24, 2008 02:00 ET
|
Merrion Pharmaceuticals plc
DUBLIN, Ireland, Nov. 24, 2008 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals (IEX:MERR)and Novo Nordisk A/S (NYSE:NVO), a world leader in diabetes, have entered into a Development and License Agreement...
Merrion Pharmaceuticals Receives 2008 Frost & Sullivan Osteoporosis Technology Innovation of the Year Award
November 05, 2008 05:25 ET
|
Merrion Pharmaceuticals plc
DUBLIN, Ireland, Nov. 5, 2008 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals (IEX:MERR), an international specialty pharmaceutical company, today announced that it has been awarded the Frost &...
Merrion Pharmaceuticals plc Announces Commencement of Next Stage of Oral Drug Research Collaboration Programme With Novo Nordisk
July 18, 2008 02:00 ET
|
Merrion Pharmaceuticals plc
DUBLIN, Ireland, July 18, 2008 (PRIME NEWSWIRE) -- Merrion Pharmaceuticals today announced the continuation of an oral drug delivery research collaboration programme with Novo Nordisk. This follows on...